{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:12:34Z","timestamp":1708301554581},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clinical characteristics and long-term data on the safety and efficacy of LAAC in preventing cerebrovascular accident and thromboembolism among Chinese patients with non-valvular AF (NVAF) remain limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data of consecutive NVAF patients who underwent LAAC at Beijing Anzhen Hospital, Capital Medical University, from June 1, 2014, to December 31, 2021, were collected and analyzed retrospectively. The primary effectiveness endpoint was the composite endpoint of stroke\/transient ischemic attack, systemic embolism, and death from cardiovascular causes. The primary safety endpoint is the severe bleeding defined by the LAAC Munich consensus.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 222 patients enrolled, the mean age was 66.90\u2009\u00b1\u20099.62 years, with a majority being male (77.03%). Many patients are non-paroxysmal AF (71.19%) with a median duration of AF of 4.00 years. The mean CHA2DS2-VASc score was 3.78\u2009\u00b1\u20091.49, and the mean HAS-BLED score was 1.68\u2009\u00b1\u20090.86. Thromboembolic events (76.58%) were the most common indication for LAAC. The device, technical, and procedural success rates were 98.65%, 98.65%, and 93.69%, respectively. The anticoagulation continuation rate was 56.36%, 31.25%, and 22.60% at 3-, 6- and 12 months post-procedure, respectively. Throughout a mean 2.81 years of follow-up, the incidence of the primary efficacy endpoint was 4.27 per 100 patient-years, predominantly attributable to stroke\/TIA (3.12 per 100 PYs). Five patients experienced major bleeding during the follow-up period. Post-procedure imaging revealed minimal complications, with only one substantial peri-device leak. Device-related thrombus occurred in 2.33% of patients, resolving with anticoagulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The study demonstrates that LAAC is a safe and effective alternative option for Chinese patients with AF, with a high success rate, few complications as well as fewer long-term adverse outcome events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-023-03651-8","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T11:02:18Z","timestamp":1707908538000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and outcome of patients with left atrial appendage closure in China: a single-center experience"],"prefix":"10.1186","volume":"24","author":[{"given":"Jingrui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihua","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changsheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"3651_CR1","doi-asserted-by":"crossref","unstructured":"Du X, Guo L, Xia S et al. Atrial fibrillation prevalence, awareness and management in a nationwide survey of adults in China[J]. Heart, 2021.","DOI":"10.1136\/heartjnl-2020-317915"},{"issue":"10","key":"3651_CR2","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cjca.2019.05.024","volume":"35","author":"P Meyre","year":"2019","unstructured":"Meyre P, Blum S, Berger S, et al. Risk of hospital admissions in patients with atrial fibrillation: a systematic review and meta-analysis[J]. Can J Cardiol. 2019;35(10):1332\u201343.","journal-title":"Can J Cardiol"},{"issue":"9","key":"3651_CR3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/CIRCRESAHA.114.303211","volume":"114","author":"J Andrade","year":"2014","unstructured":"Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms[J]. Circ Res. 2014;114(9):1453\u201368.","journal-title":"Circ Res"},{"issue":"10","key":"3651_CR4","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1161\/CIR.0b013e318214876d","volume":"123","author":"V Fuster","year":"2011","unstructured":"Fuster V, Ryd\u00e9n LE, Cannom DS, et al. 2011 ACCF\/AHA\/HRS focused updates incorporated into the ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation[J]. Circulation. 2011;123(10):e269\u2013e367.","journal-title":"Circulation"},{"issue":"32","key":"3651_CR5","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1093\/eurheartj\/ehy411","volume":"39","author":"JC Cowan","year":"2018","unstructured":"Cowan JC, Wu J, Hall M, et al. A 10 year study of hospitalized atrial fibrillation-related Stroke in England and its association with uptake of oral anticoagulation[J]. Eur Heart J. 2018;39(32):2975\u201383.","journal-title":"Eur Heart J"},{"key":"3651_CR6","doi-asserted-by":"crossref","unstructured":"Guo Y, Kotalczyk A, Imberti JF et al. Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation. A report from the optimal Thromboprophylaxis in elderly Chinese patients with atrial fibrillation (ChiOTEAF) registry[J]. Eur Heart J Qual Care Clin Outcomes, 2021.","DOI":"10.1093\/ehjqcco\/qcab054"},{"issue":"11","key":"3651_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in patients with Atrial Fibrillation[J]. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"10","key":"3651_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"issue":"12","key":"3651_CR9","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"2","key":"3651_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","volume":"61","author":"JL Blackshear","year":"1996","unstructured":"Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation[J]. Ann Thorac Surg. 1996;61(2):755\u20139.","journal-title":"Ann Thorac Surg"},{"key":"3651_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ahj.2016.05.007","volume":"178","author":"GY Lip","year":"2016","unstructured":"Lip GY, Hammerstingl C, Marin F, et al. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF)[J]. Am Heart J. 2016;178:126\u201334.","journal-title":"Am Heart J"},{"issue":"9689","key":"3651_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","volume":"374","author":"DR Holmes","year":"2009","unstructured":"Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial[J]. Lancet. 2009;374(9689):534\u201342.","journal-title":"Lancet"},{"issue":"1","key":"3651_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","volume":"64","author":"DR Holmes Jr","year":"2014","unstructured":"Holmes DR Jr., Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial[J]. J Am Coll Cardiol. 2014;64(1):1\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3651_CR14","doi-asserted-by":"publisher","first-page":"e2214594","DOI":"10.1001\/jamanetworkopen.2022.14594","volume":"5","author":"F Su","year":"2022","unstructured":"Su F, Gao C, Liu J, et al. Periprocedural outcomes associated with Use of a left atrial appendage occlusion device in China[J]. JAMA Netw Open. 2022;5(5):e2214594.","journal-title":"JAMA Netw Open"},{"key":"3651_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijcard.2022.08.007","volume":"368","author":"M Chen","year":"2022","unstructured":"Chen M, Sun J, Wang QS, et al. Long-term outcome of combined catheter ablation and left atrial appendage closure in atrial fibrillation patients[J]. Int J Cardiol. 2022;368:41\u20138.","journal-title":"Int J Cardiol"},{"issue":"7","key":"3651_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/pace.14292","volume":"44","author":"J Wang","year":"2021","unstructured":"Wang J, Rong B, Zhang K, et al. Feasibility and safety of left atrial appendage occlusion guided by procedural fluoroscopy only: a pilot study[J]. Pacing Clin Electrophysiol. 2021;44(7):1207\u201315.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"13","key":"3651_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4244\/EIJY19M08_01","volume":"15","author":"M Glikson","year":"2020","unstructured":"Glikson M, Wolff R, Hindricks G, et al. EHRA\/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update[J]. EuroIntervention. 2020;15(13):1133\u201380.","journal-title":"EuroIntervention"},{"issue":"8","key":"3651_CR18","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1210\/en.2018-00465","volume":"159","author":"M Roy-O\u2019Reilly","year":"2018","unstructured":"Roy-O\u2019Reilly M, McCullough LD. Age and sex are critical factors in ischemic stroke pathology[J]. Endocrinology. 2018;159(8):3120\u201331.","journal-title":"Endocrinology"},{"issue":"6","key":"3651_CR19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/pace.13020","volume":"40","author":"Y Chen","year":"2017","unstructured":"Chen Y, Zhang Y, Huang W, et al. Primary and secondary stroke prevention using left atrial appendage closure with watchman devices in atrial fibrillation patients: a single center experience from Mainland China[J]. Pacing Clin Electrophysiol. 2017;40(6):607\u201314.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"4","key":"3651_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4103\/0366-6999.199832","volume":"130","author":"WP Huang","year":"2017","unstructured":"Huang WP, Zhang YH, He L, et al. Efficacy and safety of the WATCHMAN left atrial appendage system for stroke prevention in Chinese patients with nonvalvular atrial fibrillation: a single-center, prospective, observational study[J]. Chin Med J (Engl). 2017;130(4):434\u20138.","journal-title":"Chin Med J (Engl)"},{"key":"3651_CR21","doi-asserted-by":"publisher","first-page":"719755","DOI":"10.3389\/fcvm.2021.719755","volume":"8","author":"BF Mo","year":"2021","unstructured":"Mo BF, Zhang R, Yuan JL, et al. Left atrial appendage closure for primary and secondary stroke prevention in patients with hypertrophic cardiomyopathy and atrial fibrillation: a pilot Study[J]. Front Cardiovasc Med. 2021;8:719755.","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"3651_CR22","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.hrthm.2017.05.038","volume":"14","author":"LV Boersma","year":"2017","unstructured":"Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial[J]. Heart Rhythm. 2017;14(9):1302\u20138.","journal-title":"Heart Rhythm"},{"issue":"13","key":"3651_CR23","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2019.12.040","volume":"75","author":"JV Freeman","year":"2020","unstructured":"Freeman JV, Varosy P, Price MJ, et al. The NCDR Left Atrial appendage occlusion Registry[J]. J Am Coll Cardiol. 2020;75(13):1503\u201318.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"3651_CR24","doi-asserted-by":"publisher","first-page":"e2220597","DOI":"10.1001\/jamanetworkopen.2022.20597","volume":"5","author":"DA McNamara","year":"2022","unstructured":"McNamara DA, Chopra R, Decker JM, et al. Comparison of Radiation exposure among interventional echocardiographers, interventional cardiologists, and Sonographers during Percutaneous Structural Heart Interventions[J]. JAMA Netw Open. 2022;5(7):e2220597\u20137.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"3651_CR25","first-page":"314","volume":"21","author":"Z Zhai","year":"2019","unstructured":"Zhai Z, Tang M, Su X, et al. Experience of left atrial appendage occlusion with the WATCHMAN device in Chinese patients[J]. Anatol J Cardiol. 2019;21(6):314\u201321.","journal-title":"Anatol J Cardiol"},{"key":"3651_CR26","doi-asserted-by":"crossref","unstructured":"Chiu F-C, Huang P-S, Chen J-J, et al. Long-term outcomes of percutaneous left atrial appendage closure for the prevention of Stroke in patients with atrial fibrillation: Asia-Pacific experience[J]. Journal of the Formosan Medical Association\u2009=\u2009Taiwan yi zhi; 2021.","DOI":"10.1016\/j.jfma.2021.10.010"},{"issue":"12","key":"3651_CR27","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1097\/CM9.0000000000000855","volume":"133","author":"M Chen","year":"2020","unstructured":"Chen M, Wang ZQ, Wang QS, et al. One-stop strategy for treatment of atrial fibrillation: feasibility and safety of combining catheter ablation and left atrial appendage closure in a single procedure[J]. Chin Med J (Engl). 2020;133(12):1422\u20138.","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"3651_CR28","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/europace\/euy025","volume":"20","author":"L Wintgens","year":"2018","unstructured":"Wintgens L, Romanov A, Phillips K, et al. Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry[J]. Europace. 2018;20(11):1783\u20139.","journal-title":"Europace"},{"issue":"1","key":"3651_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/pace.13845","volume":"43","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Li F, Li D, et al. Efficacy and safety of catheter ablation combined with left atrial appendage occlusion for nonvalvular atrial fibrillation: a systematic review and meta-analysis[J]. Pacing Clin Electrophysiol. 2020;43(1):123\u201332.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"9","key":"3651_CR30","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1161\/CIRCULATIONAHA.118.035090","volume":"138","author":"SR Dukkipati","year":"2018","unstructured":"Dukkipati SR, Kar S, Holmes DR, et al. Device-related Thrombus after Left Atrial Appendage Closure: incidence, predictors, and Outcomes[J]. Circulation. 2018;138(9):874\u201385.","journal-title":"Circulation"},{"issue":"12","key":"3651_CR31","first-page":"1629","volume":"4","author":"M Alkhouli","year":"2018","unstructured":"Alkhouli M, Busu T, Shah K, et al. Incidence and clinical impact of device-related Thrombus following percutaneous left atrial appendage Occlusion[J]. JACC: Clin Electrophysiol. 2018;4(12):1629\u201337.","journal-title":"JACC: Clin Electrophysiol"},{"issue":"14","key":"3651_CR32","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.jacc.2018.01.076","volume":"71","author":"L Fauchier","year":"2018","unstructured":"Fauchier L, Cinaud A, Brigadeau F, et al. Device-related Thrombosis after percutaneous left atrial appendage occlusion for Atrial Fibrillation[J]. J Am Coll Cardiol. 2018;71(14):1528\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"3651_CR33","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.112.114389","volume":"127","author":"VY Reddy","year":"2013","unstructured":"Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for Stroke prophylaxis in patients with atrial fibrillation: 2.3-Year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in patients with Atrial Fibrillation) Trial[J]. Circulation. 2013;127(6):720\u20139.","journal-title":"Circulation"},{"issue":"7","key":"3651_CR34","doi-asserted-by":"publisher","first-page":"E1019","DOI":"10.1002\/ccd.29458","volume":"97","author":"A Sedaghat","year":"2021","unstructured":"Sedaghat A, Nickenig G, Schrickel JW, et al. Incidence, predictors and outcomes of device-related thrombus after left atrial appendage closure with the WATCHMAN device-insights from the EWOLUTION real world registry[J]. Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography & Interventions. 2021;97(7):E1019\u201324.","journal-title":"Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography & Interventions"},{"issue":"8","key":"3651_CR35","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jcin.2010.04.017","volume":"3","author":"RS Schwartz","year":"2010","unstructured":"Schwartz RS, Holmes DR, Van Tassel RA, et al. Left atrial appendage obliteration: mechanisms of healing and intracardiac integration[J]. JACC Cardiovasc Interv. 2010;3(8):870\u20137.","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"3651_CR36","first-page":"766","volume":"8","author":"M Alkhouli","year":"2022","unstructured":"Alkhouli M, Du C, Killu A, et al. Clinical impact of residual leaks following left atrial appendage Occlusion[J]. JACC: Clin Electrophysiol. 2022;8(6):766\u201378.","journal-title":"JACC: Clin Electrophysiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03651-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-023-03651-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03651-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T23:07:48Z","timestamp":1708297668000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-023-03651-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3651"],"URL":"https:\/\/doi.org\/10.1186\/s12872-023-03651-8","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research has undergone review and approval by the Ethics Committee of Beijing Anzhen Hospital affiliated Capital Medical University. The approval reference number is GZR-2-080. This study strictly adheres to the guidelines and regulations established by the ethics committee and was conducted in accordance with the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from all participants involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}